The National Institute for Health and Care Research funds health and care research to improve health and wellbeing.
Portfolio
3
companies
52North
52North develops diagnostic tools and digital platforms to transform urgent care pathways in oncology.
Calla Lily Clinical Care
Developing advanced drug delivery systems for women's healthcare.
Motilent
Motilent develops artificial intelligence medical image analysis software for assessing digestive diseases.
Raffaella Roncone
Head of Innovation and Enterprises for NIHR’s i4i programme
Michael Lewis
Scientific Director for Innovation
Michael brings life sciences and healthcare innovation experience from roles including Scientific Director for Innovation at the National Institute for Health and Care Research, Professor of Life Science Innovation at the University of Birmingham, and chairmanships at Open Bionics and BioMonde GmbH.
LinkedInThe funding will support the development of the Callavid drug-device combination for threatened miscarriage.
"this new product will be extremely welcomed by miscarriage patients. Pessary leakage is a recurring issue amongst my patients, causing acute anxiety and significant inconvenience during a very difficult time."
The funding round was co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co.
"This round represents a significant leap forward for 52North. With support from both UK and US healthcare leaders, we can expand our product pipeline working with major strategic partners and appropriately leverage the latest tools including AI to reshape urgent care pathways for patients worldwide. The commitment from both KHP Ventures and Cedars-Sinai exemplifies the belief in our vision and the value of our solutions."
The grant will fund the rollout of gut-imaging technology to over 10 National Health Service trusts.
"One of the first questions we are asked is 'who else is using GIQuant?' and through this grant, we have an opportunity to really drive the tech into a lot of different types of hospitals and give the clinical community the time (and resource) to see how GIQuant can fit their workflows. This of course builds on regulatory clearance and a large number of published papers, but there is no substitution for hands-on use."